SAB Biotherapeutics, Inc. (SABS) - What Are Investment Firms Saying About This Stock?

Key Points

• Analyst sentiment is cautiously positive: Eleven brokerages give SAB Biotherapeutics an average “Moderate Buy” rating, with nine buys, one hold and one sell. The average 12-month price target is $12.00.
• Institutional ownership remains limited but some firms increased positions: Hedge funds and other institutional investors own 7.82% of the stock, while Bank of America and Kestra Advisory Services significantly expanded their holdings.
• The stock faces ongoing financial pressure: Shares opened at $2.84, near the bottom of their $2.44–$5.15 one-year range, and the company reported a quarterly loss of $0.28 per share. Analysts expect a full-year loss of $1.17 per share.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $12.00.

SABS has been the topic of several analyst reports. Weiss Ratings upgraded SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 17th. Wall Street Zen raised shares of SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 10th.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new position in SAB Biotherapeutics in the 1st quarter valued at about $29,000. IFP Advisors Inc acquired a new stake in shares of SAB Biotherapeutics during the 2nd quarter worth approximately $151,000. Bank of America Corp DE increased its holdings in shares of SAB Biotherapeutics by 424.8% during the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company's stock worth $213,000 after buying an additional 45,084 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in shares of SAB Biotherapeutics by 434.6% during the 1st quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company's stock worth $236,000 after buying an additional 50,191 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of SAB Biotherapeutics during the 2nd quarter valued at approximately $421,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $2.84 on Friday. SAB Biotherapeutics has a one year low of $2.44 and a one year high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a market cap of $258.40 million, a PE ratio of -2.18 and a beta of 0.58. The stock has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.58.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). Equities research analysts expect that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals' plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.